TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19143666
Drug: High-threshold group
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-threshold group (phototherapy interrupted when TSB decreased to >/=1 mg/dL below limit)
Study: 19143666
Drug: Low-threshold group
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-threshold group (phototherapy interrupted when TSB decreased to >/=3 mg/dL below limit)
Study: 15200755
Drug: Ezetimibe 10
Normalized name: ezetimibe 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe 10 mg plus lovastatin 40 mg
Study: 15200755
Drug: Lovastatin 20
Normalized name: lovastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lovastatin 20 mg alone
Study: 3055325
Drug: Disulfiram administration
Normalized name: Disulfiram
DrugBank: Disulfiram (DB00822)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Disulfiram administration (Group 1)
Study: 23815562
Drug: Olmesartan/Amlodipine combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olmesartan/Amlodipine combination (20/5 mg)
Study: 16091994
Drug: Breathing rate
Normalized name: cetylpyridinium chloride Mouthwash [Breath-Away]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Breathing rate of 10 L/min
Study: 12173800
Drug: Aerosolized ceftazidime
Normalized name: Ceftazidime
DrugBank: Ceftazidime (DB00438)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aerosolized ceftazidime 250 mg every 12 hours for up to 7 days
Study: 21452030
Drug: HPV vaccine
Normalized name: HPV vaccine 9-valent/PF 0.5 mL INTRAMUSC VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPV vaccine radionovela
Study: 12150647
Drug: Group Cognitive-Behavioral
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group Cognitive-Behavioral Therapy (CBT)
Study: 19176275
Drug: Enhanced Supportive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced Supportive Therapy (ST)
Study: 17101746
Drug: Modified-release zolpidem
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified-release zolpidem (12.5 mg)
Study: 17101746
Drug: Immediate-release zolpidem
Normalized name: zolpidem Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release zolpidem (10 mg)
Study: 15233714
Drug: Conflict-oriented in-patient
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conflict-oriented in-patient therapy
Study: 15233714
Drug: Systemic out-patient
Normalized name: Cough Out
DrugBank: Guaifenesin (DB00874)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Systemic out-patient therapy
Study: 3113339
Drug: Conventional-dose group:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional-dose group: 600 mg of tegafur p.o. daily and 1-2 mg of lentinan i.v. weekly
Study: 20973459
Drug: High-calcium fortified
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-calcium fortified milk (400 ml daily for 16 weeks)
Study: 2048623
Drug: Occupational therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Occupational therapy intervention related to leisure activities
Study: 28977347
Drug: Nutritional supplementation
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional supplementation (150 kcal, 20 g whey protein, 800 IU vitamin D, 119 mL beverage)
Study: 28977347
Drug: Placebo (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (30 kcal, nonnutritive, 119 mL)
Study: 26501267
Drug: Omega-3 PUFAs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 PUFAs (600 mg EPA and 625 mg DHA per day)
Study: 22691248
Drug: L. reuteri
Normalized name: L. reuteri
DrugBank: Lactobacillus reuteri (DB14224)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L. reuteri (108 CFU = 5 drops per day) for 60 days
Study: 12524069
Drug: Flutamide (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flutamide (250 mg daily)
Study: 9135694
Drug: Finasteride (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Finasteride (5 mg daily)
Study: 10501359
Drug: Nebulised fenoterol
Normalized name: fenoterol
DrugBank: Fenoterol (DB01288)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulised fenoterol (after initial treatment)
Study: 8927681
Drug: Olanzapine (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine (two doses)
Study: 1909692
Drug: Placebo (0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0.05 ml/kg/day)
Study: 6832465
Drug: Dithranol cream
Normalized name: Zithranol
DrugBank: Anthralin (DB11157)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dithranol cream 0.25%
Study: 9567231
Drug: Spinal manipulative
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal manipulative therapy
Study: 10825039
Drug: Intradermal bacille
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal bacille Calmette‐Guérin (BCG) vaccination
Study: 31377269
Drug: Methylnaltrexone (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylnaltrexone (0.3 mg/kg intravenous)
Study: 28127644
Drug: Far Infrared
Normalized name: Menthol/Methyl Salicylate 3%-0.5% Topical application Patch, Extended Release [GOLDEN SUNSHINE FAR INFRARED HOT HERBAL]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Far Infrared Radiation (FIR) treatment
Study: 9333593
Drug: Magnesium treatment
Normalized name: Magnesium
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium treatment
Study: 6093241
Drug: Cefotaxime (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotaxime (1 g i.m. every 12 hours to a total of 3 g)
Study: 16761235
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no antibiotic)
Study: 21034160
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy of MSX and CC
Study: 16938159
Drug: Haloperidol 1
Normalized name: haloperidol 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol 1 mg intravenous
Study: 12552184
Drug: Ondansetron 4
Normalized name: ondansetron 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 4 mg intravenous
Study: 16602440
Drug: Serum copper
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum copper concentration in RA patients (19.1 +/- 4.5 micromol/L)
Study: 12379846
Drug: Pre-aggregated Abeta42
Normalized name: Albumin Aggregated
DrugBank: Albumin Aggregated (DB14230)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-aggregated Abeta42 vaccination (primary injection followed by booster injection)
Study: 9627891
Drug: Mandibular implant-supported
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mandibular implant-supported overdentures
Study: 7936862
Drug: Measles-mumps-rubella-varicella vaccine
Normalized name: varicella-zoster virus vaccine live (Oka-Merck) strain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Measles-mumps-rubella-varicella vaccine
Study: 23926584
Drug: All-on-2 implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: All-on-2 implants
Study: 23926584
Drug: All-on-4 implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: All-on-4 implants
Study: 12520528
Drug: ED-71 (0.25,
Approvals — FDA: no, EMA: no, PMDA: no
Description: ED-71 (0.25, 0.5, 0.75, and 1.0 microgram) administered orally daily for 6 months
Study: 11099743
Drug: Fluoxetine 20
Normalized name: fluoxetine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine 20 mg + Clonazepam 0.5-1.0 mg
Study: 7815703
Drug: Midazolam 4
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam 4 mg
Study: 8968175
Drug: Midazolam 8
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam 8 mg
Study: 27029706
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus weekly paclitaxel
Study: 24882176
Drug: Therapist-assisted internet
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapist-assisted internet cognitive behavioural treatment (iCBT) program
Study: 23864802
Drug: D-002 (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-002 (100 mg/day)
Study: 17024953
Drug: Red wine
Normalized name: Red wine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red wine staining solution
Study: 17024953
Drug: Night Effects
Approvals — FDA: no, EMA: no, PMDA: no
Description: Night Effects bleaching agent
Study: 17024953
Drug: Simply White
Normalized name: SODIUM FLUORIDE 0.0024 g in 1 g DENTAL PASTE, DENTIFRICE [Simply White Sweet Mint]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simply White Night bleaching agent
Study: 17024953
Drug: Opalescence Quick
Normalized name: Cal-Quick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opalescence Quick bleaching agent
Study: 23544125
Drug: Ezetimibe 10
Normalized name: ezetimibe 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe 10 mg/d
Study: 10406828
Drug: Troglitazone (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Troglitazone (400 mg/d)
Study: 27417982
Drug: Low-intensity strategy
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-intensity strategy (control arm) utilizing a licensed practical nurse for bi-monthly, non-tailored behavioral support calls.
Study: 23910952
Drug: Algorithm-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Algorithm-based treatment with basal-bolus insulin therapy
Study: 8096956
Drug: Mefloquine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mefloquine (25 mg/kg)
Study: 15904617
Drug: Laparoscopic hysterectomy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laparoscopic hysterectomy with vaginal cuff suspension (LHS group)
Study: 15904617
Drug: Laparoscopic hysterectomy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laparoscopic hysterectomy without vaginal cuff suspension (LH group)
Study: 8760238
Drug: Control infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control infusion of Hartman's solution at 4 ml/min for 210 min
Study: 1718364
Drug: Cisapride 20
Normalized name: cisapride 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride 20 mg given orally with MST 20 mg
Study: 6808542
Drug: Low nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low nicotine content (0.2 mg) cigarette
Study: 30465630
Drug: mHealth technology‐enabled,
Approvals — FDA: no, EMA: no, PMDA: no
Description: mHealth technology‐enabled, nurse‐guided intervention with a Blue-toothed BP device and smartphone App for monitoring BP measurements and medication intake for three months
Study: 25822674
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of radioisotope and blue dye
Study: 24054830
Drug: Ciprofloxacin DPI
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciprofloxacin DPI 65 mg once daily (qd) for 7 days (n=6)
Study: 24054830
Drug: Ciprofloxacin DPI
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciprofloxacin DPI 32.5 mg twice daily (bid) for 7 days (n=6)
Study: 10922131
Drug: Both therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both therapies
Study: 11576818
Drug: Hormone therapy
Normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hormone therapy
Study: 11788660
Drug: Carbenoxolone (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbenoxolone (100 mg every 8 h for 7 d)
Study: 10235511
Drug: WR 6026
Approvals — FDA: no, EMA: no, PMDA: no
Description: WR 6026 at 120 mg/day for 21 days
Study: 10235511
Drug: WR 6026
Approvals — FDA: no, EMA: no, PMDA: no
Description: WR 6026 at 150 mg/day for >19 days
Study: 8767368
Drug: Nocturnal oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nocturnal oxygen administration
Study: 2024744
Drug: Continuous lumbar
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous lumbar plexus block with 0.5% bupivacaine and adrenaline (0.3 ml/kg)
Study: 7014058
Drug: Aspirin, 600
Normalized name: Aspirin, 600 mg rectal suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin, 600 mg, b.i.d.
Study: 7014058
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of aspirin and hydroxychloroquine (Plaquenil), 300 mg, b.i.d.
Study: 28966304
Drug: Mild hypothermia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mild hypothermia therapy (34‐36°C)
Study: 25467190
Drug: Gabapentin enacarbil
Normalized name: Gabapentin Enacarbil
DrugBank: Gabapentin enacarbil (DB08872)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gabapentin enacarbil (GEn) 600 mg + morphine placebo
Study: 25467190
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment (GEn + morphine)
Study: 21317209
Drug: No pre-treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No pre-treatment with etch-and-rinse adhesive system (Transbond XT)
Study: 21317209
Drug: No pre-treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No pre-treatment with self-etching adhesive system (Transbond Plus)
Study: 17845276
Drug: Topiramate (100-400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topiramate (100-400 mg/day)
Study: 28524705
Drug: Intensive individualized
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive individualized nutritional and educational interventions during the entire course of chemotherapy
Study: 30767826
Drug: High-Intensity Treatment
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-Intensity Treatment (HIT)
Study: 30767826
Drug: Low-Intensity Treatment
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-Intensity Treatment (LIT)
Study: 17869635
Drug: Dabigatran etexilate
Normalized name: Dabigatran etexilate
DrugBank: Dabigatran etexilate (DB06695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dabigatran etexilate 220 mg
Study: 23519576
Drug: Dabigatran etexilate
Normalized name: Dabigatran etexilate
DrugBank: Dabigatran etexilate (DB06695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dabigatran etexilate 150 mg
Study: 16855074
Drug: FTY720 1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: FTY720 1.25 mg
Study: 16855074
Drug: FTY720 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: FTY720 5 mg
Study: 16855074
Drug: FTY720 (1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: FTY720 (1.25 mg or 5 mg)
Study: 10426879
Drug: Statin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin treatment (Simvastatin)
Study: 10426879
Drug: Statin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin treatment (not specified)
Study: 10426879
Drug: Statin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin treatment (Pravastatin)
Study: 2967477
Drug: Prednisone 30
Normalized name: prednisone 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone 30 mg
Study: 7482385
Drug: Dextroamphetamine 15
Normalized name: dextroamphetamine 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextroamphetamine 15 mg
Study: 28533100
Drug: Remote ischaemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remote ischaemic conditioning (RIC) treatment, performed twice a day for 6 weeks
Study: 27914656
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg oral omecamtiv mecarbil twice daily (fixed-dose group)
Study: 27914656
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg twice daily titrated to 50 mg twice daily (pharmacokinetic-titration group)
Study: 27914656
Drug: Pharmacokinetic-titration group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacokinetic-titration group
Study: 16105530
Drug: 0.5 microg
Normalized name: calcitriol 0.5 MICROGRAM In 1 CAPSULE ORAL CAPSULE, LIQUID FILLED [Rocaltrol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 microg of calcitriol twice per day (group A)
Study: 2047050
Drug: Low-dose triphasic
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose triphasic oral contraceptives (ethinyl estradiol and levonorgestrel)
Study: 2047050
Drug: Low-dose triphasic
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose triphasic oral contraceptives (ethinyl estradiol and norethindrone)
Study: 25761430
Drug: Amlodipine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine (10 mg p.d.)
Study: 25761430
Drug: Ranolazine (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranolazine (750 mg b.i.d.)
Study: 21323491
Drug: Tailored fluorouracil,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tailored fluorouracil, epirubicin, and cyclophosphamide (FEC) therapy at dose step 4
Study: 21323491
Drug: Tailored fluorouracil,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tailored fluorouracil, epirubicin, and cyclophosphamide (FEC) therapy at dose steps -2 and -1 (combined)
Study: 21323491
Drug: Tailored fluorouracil,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tailored fluorouracil, epirubicin, and cyclophosphamide (FEC) therapy (all dose steps)
Study: 20306761
Drug: Chemical medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemical medicine (not specified)
Study: 20306761
Drug: Placebo (inert
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (inert pill)
Study: 7948453
Drug: Antipsychotic medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antipsychotic medication
Study: 31664343
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (45 minutes) and sham VR program (15 minutes)
Study: 23835207
Drug: Governmentally-led physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Governmentally-led physical activity program (Youp'là Bouge) implemented in 58 child care centers, including training of educators, adaptation of the built environment, parental involvement, and daily physical activity from September 2009 to June 2010.
Study: 9659302
Drug: Healing sessions
Normalized name: Alternanthera sessilis extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Healing sessions (10 weekly sessions)
Study: 6790048
Drug: Oxprenolol (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxprenolol (40 mg)
Study: 19433558
Drug: Posaconazole administered
Normalized name: Posaconazole
DrugBank: Posaconazole (DB01263)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Posaconazole administered via nasogastric tube (400 mg)
Study: 19433558
Drug: Posaconazole administered
Normalized name: Posaconazole
DrugBank: Posaconazole (DB01263)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Posaconazole administered orally (400 mg)
Study: 10952323
Drug: Heparin group
Normalized name: Heparin group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin group
Study: 4038553
Drug: Oral dexamethasone
Normalized name: dexamethasone Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dexamethasone (2-week tapering dose from 0.15 mg/kg/d)
Study: 27817208
Drug: Liraglutide 3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide 3.0 mg
Study: 17506591
Drug: Imidapril (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imidapril (5 mg/day to 20 mg/day)
Study: 17506591
Drug: Candesartan cilexetil
Normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Candesartan cilexetil (4 mg/day to 16 mg/day)
Study: 31133052
Drug: Intravenous hydration
Normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous hydration (aggressive or routine)
Study: 15649850
Drug: Oral slow-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral slow-release theophylline (Theo-Dur, 600 mg tablets)
Study: 15649850
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of salmeterol and theophylline
Study: 15649850
Drug: Theophylline (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline (600 mg)
Study: 11960266
Drug: Blood stem
Normalized name: Autologous Hematopoietic Peripheral Blood Stem Cells
DrugBank: Autologous Hematopoietic Peripheral Blood Stem Cells (DB17067)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood stem cell (BSC) donation with G-CSF 10 microg/kg s.c., daily for 5 days before leukapheresis
Study: 8602746
Drug: Interferon beta‐1a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon beta‐1a (6.0 million units, 30 micrograms, administered by intramuscular injection weekly)
Study: 20472939
Drug: Surfactant treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surfactant treatment
Study: 2011088
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy with mechanical ventilation alone (Control)
Study: 7156001
Drug: Double blind
Normalized name: Io-Blend
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double blind ribosomal vaccine
Study: 25268853
Drug: Transdermal 17β
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal 17β estradiol (t‐E2) 50 μg/day plus micronized progesterone (m‐P) for 12 days
Study: 25268853
Drug: Oral conjugated
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral conjugated equine estrogen (o‐CEE) 0.45 mg/day plus micronized progesterone (m‐P) for the first 12 days of the month
Study: 9477042
Drug: Daflon 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daflon 500 mg
Study: 30139537
Drug: Patient selection
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient selection by the number of prescribed drugs
Study: 17545008
Drug: Calcineurin inhibitors
Normalized name: Calcineurin inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcineurin inhibitors
Study: 17499035
Drug: Intracavity triamcinolone
Normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracavity triamcinolone 80 mg (Group A, n=29)
Study: 17499035
Drug: Intracavity triamcinolone
Normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracavity triamcinolone 80 mg (Group A)
Study: 12798615
Drug: vax‐TyVi (Salmonella
Approvals — FDA: no, EMA: no, PMDA: no
Description: vax‐TyVi (Salmonella Typhi Vi polysaccharide vaccine)